Bayer's Nexavar meets goal in thyroid cancer trial
FRANKFURT Jan 3 (Reuters) - German drugmaker Bayer said its drug Nexavar reached a goal of improving the survival of patients with a certain type of thyroid cancer in a late-stage trial.
It said on Thursday it plans to submit data from the trial as the basis for marketing approval of Nexavar to treat radioactive iodine refractory differentiated thyroid cancer. (Reporting by Maria Sheahan)
- Pope attacks mega-salaries and wealth gap in peace message
- Air strike kills 15 civilians in Yemen by mistake: officials
- Probation for drunk Texas teen driver who killed four sparks backlash
- Atheists face death in 13 countries, global discrimination: study
- South Africa admits error over 'schizophrenic' Mandela signer |